<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00286156</url>
  </required_header>
  <id_info>
    <org_study_id>7736</org_study_id>
    <nct_id>NCT00286156</nct_id>
  </id_info>
  <brief_title>Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)</brief_title>
  <official_title>Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, open-label, pilot clinical trial designed to compare
      the effects of an agent that has antiproliferative (1,2), antiangiogenesis (3),and
      tumor-progression blocking capabilities (4), namely, rapamycin (Rapamune®), in the treatment
      of autosomal-dominant polycystic kidney disease (ADPKD).

      Up to this time, only generic renal disease treatments for ADPKD have been in use, such as
      the treatment of hypertension, urinary tract infections, renal stones, renal call carcinomas,
      and replacement therapy with dialysis and/or renal transplantation. The fundamental
      aberrations in ADPKD are proliferation of cyst-forming tubuloepithelial cells, secretion of
      cytokine-rich fluid into those cysts, and progressive cyst expansion and release of
      inflammatory mediators that injure surrounding normal renal tissue. Consequently, therapy
      directed specifically at blocking the proliferation of tubuloepithelial cells and their
      tendency to malignant transformation, as well as impeding their blood supply, should have
      obvious merit.

      General Procedures:

      In Group I participants will have an iothalamate glomerular filtration rate (GFR) equal to or
      greater than 60 ml/min/1.73 m2, and in Group II participants will have a GFR less than 25-59
      ml/min/1.73 m2. Both males and females with ADPKD who volunteer and qualify, will be randomly
      and prospectively assigned to treatment with rapamycin at either a high or low trough blood
      level or to standard care (each 1/3 of enrolled patients) for one year. The two treatment
      groups will receive rapamycin doses aimed at maintaining the 20- to 24-hour trough blood
      levels at either 2 to 5 ng/mL (low-dose), or greater than 5 to 8 ng/mL (high-dose). These
      trough levels are in the lower range of levels used when treating renal transplant recipients
      in whom trough levels are typically maintained between 5 and 15 ng/mL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized,open label, pilot clinical trial designed to compare
      the effects of an agent that has antiproliferative (1,2), antiangiogenesis (3),and
      tumor-progression blocking capabilities (4), namely, rapamycin (Rapamune®), in the treatment
      of autosomal-dominant polycystic kidney disease (ADPKD).

      Up to this time, only generic renal disease treatments for ADPKD have been in use, such as
      the treatment of hypertension, urinary tract infections, renal stones, renal call carcinomas,
      and replacement therapy with dialysis and/or renal transplantation. The fundamental
      aberrations in ADPKD are proliferation of cyst-forming tubuloepithelial cells, secretion of
      cytokine-rich fluid into those cysts, and progressive cyst expansion and release of
      inflammatory mediators that injure surrounding normal renal tissue. Consequently, therapy
      directed specifically at blocking the proliferation of tubuloepithelial cells and their
      tendency to malignant transformation, as well as impeding their blood supply, should have
      obvious merit.

      General Procedures:

      In Group I participants will have an iothalamate glomerular filtration rate (GFR) equal to or
      greater than 60 ml/min/1.73 m2, and in Group II participants will have a GFR less than 25-59
      ml/min/1.73 m2. Both males and females with ADPKD who volunteer and qualify, will be randomly
      and prospectively assigned to treatment with rapamycin at either a high or low trough blood
      level or to standard care (each 1/3 of enrolled patients) for one year. The two treatment
      groups will receive rapamycin doses aimed at maintaining the 20- to 24-hour trough blood
      levels at either 2 to 5 ng/mL (low-dose), or greater than 5 to 8 ng/mL (high-dose). These
      trough levels are in the lower range of levels used when treating renal transplant recipients
      in whom trough levels are typically maintained between 5 and 15 ng/mL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in GFR From Baseline to 12 Months</measure>
    <time_frame>From baseline to 12 months</time_frame>
    <description>GFR (glomerular filtration rate) was measured by iothalamate. GFR is a key indicator of renal function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Kidney Volume as Measured by 3D-CT From Baseline to 12 Months</measure>
    <time_frame>From baseline to 12 months</time_frame>
    <description>Total kidney volume measured by CT from baseline to 12 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Polycystic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamune</intervention_name>
    <description>Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ADPKD

          -  &gt; 18 y.o. GFR greater than or equal to 25. Willingness to be randomized to any
             treatment group Willingness to follow protocol requirements-frequent testing and
             follow-up required at Cleveland Clinic(Cleveland, OH) signed informed consent
             Willingness to use birth control(male and female)

        Exclusion Criteria:

          -  Pregnancy

          -  post partum

          -  lactating

          -  system illness with renal involvement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William E. Braun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cleveland Clinic- main campus</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2006</study_first_submitted>
  <study_first_submitted_qc>February 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2006</study_first_posted>
  <results_first_submitted>March 31, 2015</results_first_submitted>
  <results_first_submitted_qc>March 31, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2015</results_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADPKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Rapamycin Dose (STD)</title>
          <description>Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml
Rapamycin: Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Rapamycin (LD)</title>
          <description>Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml
Rapamycin: Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml</description>
        </group>
        <group group_id="P3">
          <title>Standard Care</title>
          <description>Standard Care: fluid intake primarily water of 2500-3000ml/24hrs, low sodium diet of 2300mg/24 hrs, caffeine avoidance, control of hypertension</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missed 12 month visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE: pulmonary embolus</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE: nephrotic-range proteinuruia</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE: pneumonia</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Rapamycin Dose (STD)</title>
          <description>Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml
Rapamycin: Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Rapamycin (LD)</title>
          <description>Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml
Rapamycin: Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml</description>
        </group>
        <group group_id="B3">
          <title>Standard Care</title>
          <description>Standard Care: fluid intake primarily water of 2500-3000ml/24hrs, low sodium diet of 2300mg/24 hrs, caffeine avoidance, control of hypertension</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="15.0"/>
                    <measurement group_id="B2" value="44.9" spread="8.6"/>
                    <measurement group_id="B3" value="49.4" spread="11.0"/>
                    <measurement group_id="B4" value="49.3" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline characteristics and risk factors</title>
          <description>ADPKD, autosomal dominant polycystic kidney disease; iGFR, 125I-iothalamate GFR; TKV, total kidney volume; Hypertension is a BP &gt;= 140/90 mmHg before 35 years old; family history of ESRD occurs from ADPKD before 56 years old</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family history of ESRD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial iGFR 25-59 ml/min per 1.73 m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial TKV&gt;1500ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial height-adjusted TKV&gt;=600ml/m</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in GFR From Baseline to 12 Months</title>
        <description>GFR (glomerular filtration rate) was measured by iothalamate. GFR is a key indicator of renal function.</description>
        <time_frame>From baseline to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Rapamycin Dose (STD)</title>
            <description>Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml
Rapamycin: Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Rapamycin (LD)</title>
            <description>Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml
Rapamycin: Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard Care: fluid intake primarily water of 2500-3000ml/24hrs, low sodium diet of 2300mg/24 hrs, caffeine avoidance, control of hypertension</description>
          </group>
        </group_list>
        <measure>
          <title>Change in GFR From Baseline to 12 Months</title>
          <description>GFR (glomerular filtration rate) was measured by iothalamate. GFR is a key indicator of renal function.</description>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline iGFR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" spread="25.7"/>
                    <measurement group_id="O2" value="70.3" spread="27.0"/>
                    <measurement group_id="O3" value="73.1" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month iGFR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="34.4"/>
                    <measurement group_id="O2" value="78.0" spread="35.0"/>
                    <measurement group_id="O3" value="61.9" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in iGFR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="12.1"/>
                    <measurement group_id="O2" value="7.7" spread="12.5"/>
                    <measurement group_id="O3" value="-11.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference between groups in iGFR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Pairwise comparisons adjusted for multiple testing (Tukey)</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Kidney Volume as Measured by 3D-CT From Baseline to 12 Months</title>
        <description>Total kidney volume measured by CT from baseline to 12 months</description>
        <time_frame>From baseline to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Rapamycin Dose (STD)</title>
            <description>Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml
Rapamycin: Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Rapamycin (LD)</title>
            <description>Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml
Rapamycin: Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard Care: fluid intake primarily water of 2500-3000ml/24hrs, low sodium diet of 2300mg/24 hrs, caffeine avoidance, control of hypertension</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Kidney Volume as Measured by 3D-CT From Baseline to 12 Months</title>
          <description>Total kidney volume measured by CT from baseline to 12 months</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline TKV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1454.1" spread="801.5"/>
                    <measurement group_id="O2" value="1919.1" spread="903.6"/>
                    <measurement group_id="O3" value="1907.1" spread="1126.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month TKV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1537" spread="864.3"/>
                    <measurement group_id="O2" value="2115.8" spread="1035.0"/>
                    <measurement group_id="O3" value="2059.8" spread="1236.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in TKV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9" spread="111.3"/>
                    <measurement group_id="O2" value="197.7" spread="201.2"/>
                    <measurement group_id="O3" value="152.7" spread="129.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Rapamycin Dose (STD)</title>
          <description>Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml
Rapamycin: Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Rapamycin (LD)</title>
          <description>Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml
Rapamycin: Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml</description>
        </group>
        <group group_id="E3">
          <title>Standard Care</title>
          <description>Standard Care: fluid intake primarily water of 2500-3000ml/24hrs, low sodium diet of 2300mg/24 hrs, caffeine avoidance, control of hypertension</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease visual acuity</sub_title>
                <description>Patient developed transient decrease in visual acuity. Neuro-ophthalmologist did not find any association with drug. Vision improved without specific treatment.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Hypoglycemia associated with excessive beer consumption.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>nephrotic range proteinuria</sub_title>
                <description>Open renal biopsy showed FSGS. Primary glomerulopathies have been reported to be superimposed on underlying ADPKD.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolus</sub_title>
                <description>Patient had massive polycystic kidneys (about 7500ml) and there was compression of the right iliac vein/IVC with clot formation. This has been reported in the literature, so it is not necessarily related to drug.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Miscellaneous/other</sub_title>
                <description>The problems in this group were minor, extremely varied and transient.</description>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Oral ulcerations</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nonserious infections</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr William Braun Consultant Staff Nephrology, Cleveland Clinic</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216/444/6995</phone>
      <email>braunw@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

